BD Showcases Advanced Biologics and Large-Volume Delivery Systems at Pharmapack 2026

BD (Becton, Dickinson and Company), a global medical technology provider, participated in Pharmapack 2026, Europe’s leading drug delivery event held at Paris Expo on January 21–22, 2026, to address emerging needs in biologic drug development and delivery. The pharmaceutical and biotech industries are increasingly focused on self-administration and home-based care models, driven by patient preference and the shift toward high-viscosity, large-volume injectable therapies such as GLP-1 treatments and vaccines. Traditional delivery systems often face technical constraints with such formulations, prompting developers to seek scalable, reliable device solutions that maintain performance while enhancing usability and traceability.

To support these evolving requirements, BD showcased its portfolio of drug delivery technologies and associated lab testing services. The company highlighted how its systems assist pharmaceutical partners in managing high-viscosity formulations, large-volume subcutaneous delivery, and complex dosing regimens, while also addressing increasing industry demand for connected manufacturing and traceable processes.

Technical Challenges and Selection Criteria
Biotech and pharmaceutical developers face significant technical hurdles when reformulating therapies originally designed for intravenous administration into formats suitable for subcutaneous self-injection. These challenges include managing viscosity, delivery volume, patient comfort, and device usability without compromising drug integrity or manufacturability. Additionally, regulatory expectations for combination products and manufacturing traceability heighten complexity for developers.

BD’s portfolio was chosen for this context because it offers integrated device solutions and testing services capable of addressing these multi-faceted challenges. The company’s offerings span from prefillable syringes engineered for lower glide force and better injection performance to wearable injectors for larger-volume biologics, as well as RFID-based traceability systems for improved process control. BD also leverages its ZebraSci services to help clients de-risk combination product development, providing technical advisory and testing support from concept through commercialization.

Deployment and Support
At Pharmapack 2026, BD demonstrated its solutions through booth presentations and live showcases. The technical program included keynote and learning lab sessions where BD experts discussed trends in high-dose biologics and strategies for evaluating delivery devices under real-world conditions, such as simulated air shipment testing. These sessions provided attendees with insights into device performance, container closure integrity, and advanced modeling approaches to support high-viscosity biologic delivery.

Although specific deployment figures were not disclosed, BD emphasized objective benefits of its solutions: improved delivery performance for challenging biologic formulations, enhanced process traceability via RFID identification, and support for scalable manufacturing practices. Live demonstrations enabled pharmaceutical partners to assess how BD’s systems might be integrated into their development workflows and manufacturing operations.

Results and Impacts
While quantitative metrics from the event itself were not available, the showcased technologies reflect measurable technical benefits important to drug developers:

BD’s contribution to the conference program and its demonstrations offered pharmaceutical companies insight into device options that align with clinical and operational goals, particularly where complex biologic therapies demand robust delivery systems.

www.bd.com